中国药物经济学2025，Vol.20Issue(7)：36-40,5.DOI:10.12010/j.issn.1673-5846.2025.07.006
化风丹治疗中风与癫痫和面神经麻痹的临床综合评价
Comprehensive Clinical Evaluation of Huafeng Dan in the Treatment of Stroke,Epilepsy and Facial Nerve Palsy
杜芸 1李艺 2戴金赫 2王孟舒 2曲淼1
作者信息
- 1. 首都医科大学宣武医院神经内科,北京 100053
- 2. 北京中医药大学第三附属医院神经内科,北京 100029
- 折叠
摘要
Abstract
Objective To evaluate comprehensive clinical of Huafeng Dan in the treatment of stroke,epilepsy and facial nerve palsy.Methods A scientific and standardized data integration analysis and comprehensive judgment combining qualitative and quantitative methods should be carried out around six dimensions:the he effectiveness,safety,economy,suitability,accessibility,innovation and characteristics of traditional Chinese medicine of of Huafeng Dan.Results Since the drug was launched on the market,clinical applications and post-marketing clinical studies(including several RCT studies)have shown that the adverse reaction symptoms of Huafeng Dan are relatively mild.It has definite therapeutic effects on stroke,epilepsy and facial nerve palsy.Compared with drugs with the same indications,its price is at a medium level and it is economically viable.Huafeng Dan,as a national intangible cultural heritage,reduces toxicity through a unique fermentation detoxification process.The dosage form design of Huafeng Dan is reasonable(water pills are convenient for patients with swallowing difficulties to take),and the clinical medication precautions are clearly marked,which can effectively guide rational drug use.Huafeng Dan has good market accessibility and its sales range covers 30 provinces,municipalities and autonomous regions.The Huafeng Pill has a history of over a hundred years of human use and has been on the market for nearly 40 years.Conclusion Huafeng Dan has good clinical value in the treatment of stroke,epilepsy and facial nerve palsy.关键词
化风丹/中风/癫痫/面神经麻痹/临床综合评价Key words
Huafeng Dan/Stroke/Epilepsy/Facial nerve paralysis/Clinical comprehensive evaluation分类
医药卫生引用本文复制引用
杜芸,李艺,戴金赫,王孟舒,曲淼..化风丹治疗中风与癫痫和面神经麻痹的临床综合评价[J].中国药物经济学,2025,20(7):36-40,5.
